SCHEMBL4244705

SCHEMBL4244705

CNC(=O)Oc1ccc(-c2n[nH]cc2C=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
ACHE P22303 6/20 0.38
ADAMTS4 O75173 1/20 0.38
THRB P10828 1/20 0.34
CDK4 P11802 1/20 0.33
CDK2 P24941 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP14 P50281 1/20 0.33
PGR P06401 1/20 0.33
GAA P10253 1/20 0.33
PTGS1 P23219 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336717 0.78 CDK4 (0.49) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4244703 0.77 SMN1; SMN2 (0.45) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL22607800 0.76 ERN1 (0.54) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4908543 0.75 ESR1 (0.41) NPC1RAB9ASMN1; SMN2MAPTMAPK1
SCHEMBL1335295 0.75 RAB9A (0.44) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL16201312 0.74 ALDH1A3 (0.49) MAPTCDK4CDK2MAPK1KMT2A
Hydrochloric Acid SCHEMBL16194267 0.73 ALDH1A3 (0.47) MAPTCDK4CDK2MAPK1KMT2A
SCHEMBL12893245 0.72 ALDH1A1 (0.51) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4246815 0.71 PTGS2 (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2CDK4
SCHEMBL1335905 0.71 XDH (0.39) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US disclosed
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US disclosed
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2009-12-10 US disclosed
EP-2057124-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM, LLC (BM) 2009-05-13 EP disclosed
WO-2008011611-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2008-01-24 WO disclosed
WO-2008011611-A2 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IRM LLC (BM) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306039-A1 COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS IP6K1, IP6K2, IP6K3 ALDH1A1 4470/4885KDM4E 1856/4885NPC1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.